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INTRODUCTION
Tissue deposition of protein fibrils causes a group of rare diseases 
called systemic amyloidosis.1 The most frequent type in high-income 
countries is AL amyloidosis, which is an acquired systemic immuno-
globulin light chain amyloidosis. There is a paucity of epidemiological 
data for this systemic disease. The first population-based study of AL 
amyloidosis in the United States came out of Olmsted County, MN, 
and was published in 1992.2 It reported the incidence of AL amyloi-
dosis as three to five cases per million population. 
This case report and literature review is intended to increase cli-
nicians’ awareness about this disease because early diagnosis of AL 
amyloidosis will have significant impact on a patient’s morbidity and 
mortality. We describe a patient who presented with the primary 
concern of syncope secondary to cardiac amyloidosis (AL-type).
CASE REPORT
An 81-year-old male with a past medical history of congestive heart 
failure with preserved ejection fraction, paroxysmal atrial fibrillation, 
monoclonal gammopathy of undetermined significance (MGUS), 
carpel tunnel syndrome, peripheral neuropathy, and chronic transu-
dative pleural effusions was referred to the hospital by his primary care 
physician with a chief complaint of syncope, which had been getting 
progressively worse over the prior two months. He also complained of 
weakness, fatigue, chronic diarrhea, numbness, tingling, easy bruising, 
and easy bleeding. The patient listed only two medications that he was 
taking, warfarin and vitamin D supplementation. 
On admission, he was afebrile. His blood pressure was 160/80 
mmHg, heart rate 91 beats per minute, respirations of 22 breaths 
per minute, and he was 99% SpO2 on room air. Orthostatic vitals 
were taken: sitting blood pressure 147/86 mmHg and pulse 89 bpm; 
standing blood pressure was 118/66 mmHg and pulse 100 bpm. He 
was awake, alert, and oriented. No scleral icterus was present. He 
had jugular venous distention. Grade II/VI systolic ejection murmur 
was noted at the right upper sternal border and 2nd intercostal space 
without radiation to the carotids. Diffuse crackles were present but no 
wheezes. There was no labored breathing. 
On abdominal examination, there was no tenderness to palpation, 
normoactive bowel sounds were present, and no masses or hepato-
splenomegaly were palpated. Rectal exam revealed a weak rectal tone 
without masses, fissures, or hemorrhoids. There was 1+ pitting edema 
to the mid-anterior shin bilaterally without cyanosis or clubbing. 
There were multiple purpuric, non-pruritic, non-blanching purplish 
lesions noted on the right neck and lower extremities. Neurological 
examination revealed no gross cranial nerve abnormalities, strength 
testing of 5/5 throughout, and normal sensation. 
Pertinent lab data revealed normocytic anemia, INR 2.2, creatinine 
1.52 mg/dL (no known baseline), urea 32 mg/dL, normal liver func-
tion tests, and normal electrolytes. Urine studies showed 2+ protein, 
1+ blood, negative nitrite, negative leukocyte esterase, and 2-5 hyaline 
casts. Brain natriuretic peptide was 1478 pg/mL and troponin mildly 
elevated at 0.08 ng/mL. TSH, aldolase, cortisol level, erythrocyte sed-
imentation rate, rheumatoid factor, anti-cyclic citrullinated peptide 
were within normal limits. Vitamin B12 was low at 276 pg/mL. He had 
an ANA elevated at 1:640 titer with a speckled pattern.
Chest x-ray revealed an enlarged cardiac silhouette, reticular linear 
opacities noted bilaterally, but no pneumothorax or alveolar con-
solidation. CT of the chest revealed reticular sub-pleural fibrosis, no 
significant honeycombing, and bilateral pleural effusions. Electrocar-
diogram (ECG) revealed a sinus rhythm, rate in the 90s, and left bundle 
branch block (baseline unknown); normal voltage criteria were met. 
A 2-D+Doppler echocardiogram revealed a left ventricular ejection 
fraction of 45%, Grade III (severe) diastolic dysfunction, moderate 
concentric bi-ventricular hypertrophy, dilated left and right atria, and 
no pericardial effusion. He had an echocardiogram four months prior 
to his admission demonstrating a left ventricular ejection fraction of 
60%, moderate concentric left ventricular hypertrophy, and Grade II 
(moderate) left ventricular diastolic dysfunction). Of note, the patient 
did not have valvular abnormalities noted on the echocardiogram but 
auscultation revealed a Grade II/VI systolic ejection murmur. One 
of the most common ascultatory findings is a systolic murmur and, 
among elderly patients, the prevalence of systolic murmurs ranges 
from 29% to 60%, and results of echocardiography are normal in 44% 
to 100% of cases.3 Cardiology was consulted because of concern for 
cardiac amyloidosis.
Cardiac catheterization revealed that the patient was unlikely to 
have a restrictive cardiomyopathy, as the diastolic pressures in both 
the right and left ventricle were below normal. Fat pad biopsy did 
not reveal amyloidosis. He followed up with outpatient cardiology 
and underwent implantation of a permanent pacemaker for symp-
tomatic tachycardia-bradycardia syndrome. He also underwent an 
endomyocardial biopsy that revealed “early stages” of AL amyloido-
sis. A bone marrow biopsy revealed 8% monoclonal lambda plasma 
cells, and free light chains showed markedly increased lambda light 
chains and mildly elevated kappa light chains. Serum protein elec-
trophoresis showed a monoclonal spike in beta/gamma regions. 
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Urine immunofixation revealed IgG lambda. The patient was referred 
to outpatient oncology where he was started on melphalan and dexa-
methasone for AL amyloidosis.
DISCUSSION
Our patient had AL amyloidosis, which is a plasma cell dyscrasia 
that is related to multiple myeloma4 and MGUS.5 The major organs 
commonly involved in AL amyloidosis are the kidney, heart, nervous 
system, skin, and gastrointestinal system. Our patient likely developed 
chronic kidney disease secondary to his underlying amyloidosis. Pro-
teinuria, cardiomyopathy, abnormal cardiac conduction, autonomic 
neuropathy, chronic diarrhea, and capillary fragility due to amyloid 
infiltration were present in our patient. The severity and number of 
organs involved determine the prognosis of AL amyloidosis. In fact, 
cardiac involvement carries the worst prognosis, with a median sur-
vival in the untreated patient of about six months from the onset of 
congestive heart failure.6 Death in cardiac AL amyloidosis occurs 
either as a result of progressive heart failure or sudden cardiac death.7 
The role of a prophylactic implantable cardioverter-defibrillator 
(ICD) remains indefinable in preventing sudden cardiac death as 
pulseless electrical activity is the most common cause of death which 
is a non-shockable rhythm. Electrocardiogram findings in amyloido-
sis may lead incorrectly to suspicion of coronary artery disease.8 On 
echocardiogram, wall thickening in amyloidosis is due to infiltration 
and, unlike true left ventricular hypertrophy in which ECG voltage is 
increased, the voltage in amyloidosis is low, providing a strong clue to 
the presence of an infiltrative myocardial disorder.9 Understanding 
what to expect on ECG or echocardiogram in a patient presenting 
with a constellation of symptoms is important in diagnosing AL amy-
loidosis.
CONCLUSION
Prompt recognition of cardiac amyloidosis is important in evalu-
ation of patients with syncope because of its poor prognosis if left 
untreated. Despite diagnostic modalities such as echocardiogram, 
computed tomography, and cytogenetic testing, history and physical 
examination remain the most valuable tools in a physician’s armamen-
tarium. In conclusion, AL amyloidosis must be suspected in patients 
presenting with syncope in the setting of autonomic neuropathy, pro-
teinuria, cardiomyopathy, chronic diarrhea, and purpura.
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